Lung Cancer Screening with Sputum Cytologic Examination, Chest Radiography, and Computed Tomography: An Update for the U.S. Preventive Services Task Force

  1. Linda L. Humphrey, MD, MPH;
  2. Steven Teutsch, MD, MPH; and
  3. Mark Johnson, MD, MPH
  1. From Oregon Health & Science University Evidence-based Practice Center and Portland Veterans Affairs Medical Center, Portland, Oregon; Merck & Co., West Point, Pennsylvania; and University of Medicine and Dentistry of New Jersey Medical School, Newark, New Jersey.
    1. Figure. Follow-up ranged from 3 to 20 years among the 6 studies. The solid black squares represent Mantel–Haenszel weight.
      View larger version:
      Figure. Follow-up ranged from 3 to 20 years among the 6 studies. The solid black squares represent Mantel–Haenszel weight. Mortality in randomized, controlled trials of lung cancer screening with chest radiography with or without sputum cytologic examination.

    Summary for Patients

    • Summaries for Patients:Screening for Lung Cancer: Recommendations from the U.S. Preventive Services Task Force Ann Intern Med May 4, 2004 140:I-88
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med May 4, 2004 vol. 140 no. 9 740-753
    1. AbstractFREE
    2. » Figures
    3. Full Text
    4. Full Text (PDF)
      1. Summary for Patients

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 3, 2009, 151 (9)
    1. Alert me to current issues